Stock overview
Gilead Sciences Inc.
Explore the company, reported ownership, price history, and available source evidence.
Gilead Sciences develops medicines for HIV, viral hepatitis, oncology, inflammation, and other serious diseases.
- Last close
- $150.93
- · GILD
- Tracked holders
- 4 funds
- Latest available 13F per fund
GILD · USD
Price
$150.93
+$39.94
(+35.99%)
over selected range
Close · Sep 25, 2026
Market closed
252 stored daily closes
$150.93
Sep 25, 2026
- Range low
- $110.56
- Range high
- $155.80
- Observations
- 252
- Session date
- Sep 25, 2026
Sep 25, 2025–Sep 25, 2026. Regular market hours only. Historical prices are unadjusted; splits and other corporate actions can affect comparisons.
Investor Popularity
Rows are narrowed by movement, fund type, and position size.
| Fund | Move | Value | Weight |
|---|---|---|---|
| Renaissance Technologies largest tracked holder Q2 2026 · filed Aug 13, 2026 · SEC filing | +3% 26'Q2 | $280,143,284 | 0.39% |
| Gotham Asset Management position history Q2 2026 · filed Aug 14, 2026 · SEC filing | +2% 26'Q2 | $48,243,055 | 0.11% |
| Tudor Investment Corp position history Q2 2026 · filed Aug 14, 2026 · SEC filing | +28% 26'Q2 | $9,462,361 | 0.01% |
|
Thrive Capital
position history
Q2 2026
· filed Aug 14, 2026
· SEC filing 1 SEC filing 2 |
+14% 26'Q2 | $4,361,698 | 0.1% |
SEC Forms 4/5
Insiders
Financials
Official-source analysis
AI Earnings Report
No published AI Earnings Report yet
We publish a cited AI Earnings Report after an eligible official earnings filing is accepted and passes validation.
Options market